Filing Details

Accession Number:
0001209191-21-060236
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-12 16:34:14
Reporting Period:
2021-10-07
Accepted Time:
2021-10-12 16:34:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808865 Iteos Therapeutics Inc. ITOS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134657 Luke Evnin C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1473930 Todd Foley C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1609492 Mpm Bioventures 2014, L.p. C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1609493 Mpm Bioventures 2014 (B), L.p. C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1609495 Mpm Asset Management Investors Bv2014 Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1729504 Mpm Bioventures 2018 (B), L.p. C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1734817 Mpm Asset Management Investors Bv2018 Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1765021 Mpm Bioventures 2014 Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1765091 Mpm Bioventures 2014 Gp Llc C/O Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-10-07 1,149 $27.00 3,259,704 No 4 S Indirect See Footnote
Common Stock Disposition 2021-10-08 2,032 $27.01 3,257,672 No 4 S Indirect See Footnote
Common Stock Disposition 2021-10-11 48,812 $27.24 3,208,860 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
  2. The shares were sold as follows: 684 by MPM BioVentures 2014, L.P. ("BV 2014"), 24 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 432 by MPM BioVentures 2018, L.P. ("BV 2018") and 9 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The shares are held as follows: 1,845,606 ,by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 63,523 by AM BV2014, 1,165,645 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 23,004 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
  5. The shares were sold as follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018 and 15 by AM BV2018.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The shares are held as follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B) and 22,989 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
  8. The shares were sold as follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by BV 2018 and 363 by AM BV2018.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. The shares are held as follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B) and 22,626 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.